Related Experiment Video

Updated: May 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Effect of RECK gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features

Tsung-Te Chung1, Chao-Bin Yeh, Yi-Ching Li

  • 1Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Plos One
|March 20, 2012
PubMed
Abstract

Insights

Genetic variations in the RECK gene, specifically certain single-nucleotide polymorphisms (SNPs), are linked to an increased risk of developing hepatocellular carcinoma (HCC) and its distant metastasis. These RECK gene polymorphisms may serve as a risk factor in Taiwan.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is frequently downregulated in various cancers.
  • RECK down-regulation correlates with increased metastasis in human cancers.
  • The role of RECK genetic variations in hepatocellular carcinoma (HCC) remains underexplored.

Purpose of the Study:

  • To investigate the association between RECK single-nucleotide polymorphisms (SNPs) and hepatocellular carcinoma (HCC) susceptibility.
  • To explore the correlation of RECK SNPs with clinicopathologic characteristics of HCC.

Main Methods:

  • Genotyping analysis of four RECK SNPs (rs10814325, rs16932912, rs11788747, and rs10972727) in 135 HCC patients and 501 controls.
  • Utilized real-time PCR and PCR-RFLP for SNP genotyping.
  • Statistical analysis adjusted for relevant co-variants.

Main Results:

  • Individuals with the RECK promoter rs10814325 C allele showed a 1.85-fold increased risk of HCC (95% CI, 1.03-3.36).
  • HCC patients carrying the rs11788747 G allele exhibited a higher risk of distant metastasis compared to wild-type carriers.
  • No significant association was found for rs16932912 and rs10972727.

Conclusions:

  • RECK gene polymorphisms, particularly rs10814325 and rs11788747, are potential risk factors for HCC susceptibility and distant metastasis.
  • These findings suggest RECK SNPs could serve as biomarkers for HCC risk and progression in the Taiwanese population.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...